3-MeO-PCE

3-MeO-PCE

is an analog of MXE (methoxetamine) — one of the more popular dissociative drugs in the arylcyclohexylamine family. Its effects are stimulating in lower doses and dissociative and hallucinogenic in higher doses.

However, tread cautiously with this one — the effects of 3-MeO-PCE are often reported as being more damaging to both the mind and body than other arylcyclohexylamines.

This compound is stronger than PCP and 3-MeO-PCP but tends to kick in more slowly (1–2 hours onset with oral use and up to 30 minutes insufflated).

Many users advise against using this drug because of its higher affinity for inducing mania than other PCP analogs. The mental stimulation of this drug can be intense — causing users to get stuck in aggressive delusional thought loops, sometimes lasting several hours at a time.

For this reason, many users report mixing it with a more sedative dissociative like DCK or ketamine or alongside a mild benzodiazepine to help offset this effect.

Even after the effects of this drug wear off, it’s common for users to experience difficulty falling asleep. Hangovers are also common with this compound — symptoms include apathy, difficulty organizing thoughts, and mild inebriated feeling.

Reports of this substance date back to at least 1979 [15], but it didn’t become popular as a research chemical until around 2010, as reported by the EMCDDA.

The receptor testing (Ki values) for 3-MeO-PCE are reported at 30.4 nM for the NMDAR, 1,528 nM for the DAT, 1,528 nM for the NET, and 136 nM for the SERT. This drug has a stronger serotonergic action than most other compounds in this class.

2-FDCK

was first synthesized in 2013 in an attempt to create and evaluate new anesthetic drugs based on ketamine. From there, it wasn’t long before it started appearing in several European countries as a ‘new psychoactive substance’ (NSP).

Chemically, 2-FDCK is classified as an arylcyclohexylamine and is the fluoro-substituted analog of ketamine.

There is virtually no peer-reviewed information on the effects profile of this dissociative psychedelic.

However, there are an increasing number of anecdotal reports of this substance appearing online as more people manage to get their hands on it.

What Are The Effects of 2-FDCK (2-Fluorodeschloroketamine)?

The effects of 2-FDCK are, unsurprisingly, reported as being quite similar to those of its parent compound, ketamine [1]. Although scientific, peer-reviewed studies are not available, there is a wealth of user-generated information that draws us to this conclusion.

Sites like Psychonaut and forums like Bluelight are places where the designer drug community congregates online in order to share their experiences with a host of different substances. This method is obviously lacking in scientific objectivity but is, in fact, quite adept at sketching out the subtle differences in the subjective effects of similar compounds.

Here are the subjective effects related to the use of 2-FDCK:

• Physical effects — Pain relief, Spontaneous physical sensations, Physical euphoria, Dizziness, Motor control loss, Nausea, Perception of bodily lightness, Physical autonomy, Spatial disorientation, Tactile suppression, Orgasm suppression
• Visual effects — Double vision, Frame rate suppression, Pattern recognition suppression, Visual acuity suppression, Distortions, Environmental cubism, Environmental orbism, Perspective distortions, Scenery slicing, Geometry, Hallucinatory states, Internal hallucination
• Cognitive effects — Anxiety suppression, Compulsive redosing, Conceptual thinking, Creativity enhancement, Déjà vu, Depersonalization, Derealization, Disinhibition, Dream potentiation, Cognitive euphoria, Immersion enhancement, Analysis suppression, Introspection, Memory suppression, Ego death, Amnesia, Time distortion, Thought deceleration, Increased music appreciation

The cognitive impacts of 2-FDCK are quite similar to those of ketamine, and some individuals may not be able to distinguish between them.

However, subjectively, the effects of 2-FDCK usually occur at a slower pace and include unique psychedelic effects that are slightly different from ketamine.

Some users also claim that higher dosages of 2-FDCK can result in more confusion and greater difficulty achieving a “hole” compared to ketamine, while others do not seem to notice this and find the experience to be just as enjoyable. Despite any differences, 2-FDCK is thought to have the same antidepressant effects as ketamine.

It should also be noted that 2F-DCK’s effects are highly dose-dependent, with lower doses producing alcohol-like intoxication and higher doses producing hallucinogenic out-of-body states (also known as a “k-hole“).

Are Arylcyclohexylamines Safe?

All members of the arylcyclohexylamine family carry a risk of toxic side effects and potential for abuse — some more than others.

The arylcyclohexylamine group contains several known toxic compounds, and all of them carry a moderate to high risk of abuse. High doses of arylcyclohexylamines can result in seizures, hyperthermia, and an increased risk of accidental injury due to disinhibition.

Long-term use can lead to the development of psychiatric disorders, cognitive decline (problems with memory and focus), or injury to the bladder, kidney, liver, and lungs.

There’s very little official research on the safety of individual arylcyclohexylamines. The exceptions are PCP and ketamine, which have been used as medicine since 1957 and 1970, respectively. This means the safety profile of most compounds in this class is not well defined.